

EMA/190118/2019

European Medicines Agency decision

P/0128/2019

of 17 April 2019

on the acceptance of a modification of an agreed paediatric investigation plan for glecaprevir / pibrentasvir (Maviret) (EMA-001832-PIP01-15-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0128/2019

of 17 April 2019

on the acceptance of a modification of an agreed paediatric investigation plan for glecaprevir / pibrentasvir (Maviret) (EMA-001832-PIP01-15-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0152/2016 issued on 14 June 2016 and the decision P/0166/2018 issued on 15 June 2018,

Having regard to the application submitted by AbbVie Ltd on 19 December 2018 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 1 March 2019, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for glecaprevir / pibrentasvir (Maviret), tablet, age-appropriate oral solid dosage form, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to AbbVie Ltd, AbbVie House, Vanwall Business Park, Vanwall Road, SL6 4UB - Maidenhead, United Kingdom.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/908916/2019

London, 1 March 2019

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001832-PIP01-15-M02

Scope of the application

Active substance(s):

Glecaprevir / pibrentasvir

Invented name:

Maviret

Condition(s):

Treatment of chronic hepatitis C

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Tablet

Age-appropriate oral solid dosage form

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

AbbVie Ltd

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, AbbVie Ltd submitted to the European Medicines Agency on 19 December 2018 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0152/2016 issued on 14 June 2016 and the decision P/0166/2018 issued on 15 June 2018.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 29 January 2019.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of chronic hepatitis C

The waiver applies to:

- the paediatric population from birth to less than 3 years of age;
- tablet, age-appropriate oral solid dosage form, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of chronic hepatitis C

2.1.1. Indication(s) targeted by the PIP

Treatment of children with genotype 1 to 6 chronic HCV infection

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Tablet and age-appropriate oral solid dosage form

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of an age-appropriate oral solid dosage form
Non-clinical studies	0	Not applicable.
Clinical studies	2	Study 2 Open-label, multicentre PK, efficacy and safety study of ABT-493/ABT-530 in children from 3 to less than 18 years of age with chronic HCV infection with the to-be-indicated genotypes Study 3 Open-label, randomised, three-period cross-over study to determine the bioavailability of the paediatric formulation relative to the adult formulation and the effect of food on the paediatric formulation

Extrapolation, modelling and simulation studies	1	Study 4 Modelling analyses to determine ABT-493/ABT-530 paediatric doses
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By September 2019
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of chronic hepatitis C

Authorised indication(s):

- Maviret is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults.

Authorised pharmaceutical form(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use